The financials
Enovis Corporation by the numbers
Enovis Corporation (ENOV) reported revenue of $589M in Q1 2026 (quarter ended April 3, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 62% and net loss of $8.8M. For the full year FY2025, revenue was $2.25B (+6.7% year on year) and net income −$1.18B. Its largest product in 2026-Q2 was Surgical at $138M, 32% of the disclosed total, just ahead of Bracing And Support at 30%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $589M | $559M | +5.4% |
| Gross profit | $365M | $332M | +10% |
| Operating income | $6.5M | −$47M | to a profit |
| Net income | −$8.8M | −$56M | n/a |
| Diluted EPS | −$0.15 | −$0.98 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Surgical | $138M | 32% |
| Bracing And Support | $128M | 30% |
| Prevention And Recovery | $101M | 24% |
| Other Prevention And Recovery | $60M | 14% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $426.1M (+1.2%)
Surgical grew +6.4% year on yearOther Prevention And Recovery -16% year on year
Segment Latestquarter on quarteryear on year
- Surgical$137.8M$137.8MQoQ -7.6%year on year +6.4%-7.6%+6.4%
- Bracing And Support$127.6M$127.6MQoQ +11%year on year +5.6%+11%+5.6%
- Prevention And Recovery$101.0M$101.0MQoQ -0.27%year on year +2.1%-0.27%+2.1%
- Other Prevention And Recovery$59.6M$59.6MQoQ +6.8%year on year -16%+6.8%-16%
- Prevention And Recovery--QoQ -year on year ---